<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454764</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-HBV-001</org_study_id>
    <nct_id>NCT02454764</nct_id>
  </id_info>
  <brief_title>'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT</brief_title>
  <official_title>To Study the Efficacy of 'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT - A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After fulfillment of the selection criteria, all the patients included in the trial will be&#xD;
      administered Tenofovir that will be continued for 3 months and then stopped for 1 month,&#xD;
      LFT's, HBV DNA, HBsAg, will be checked weekly during the time period of stopping Tenofovir&#xD;
      and thereafter at 4 months patients with ALT &gt;/= 1.5 times ULN will be randomised in 2 groups&#xD;
      to administer either Peg INF alpha 2b + Tenofovir (in same dose as before) or Tenofovir alone&#xD;
      which will be continued for 48 weeks and the patients with no rise in ALT will be excluded.&#xD;
      Patients will be closely monitored during the period of stopping tenofovir post pulse therapy&#xD;
      and liver function tests will be performed weekly. Patients will be closely observed for the&#xD;
      development of acute hepatitis or decompensation during the 4 - week period of drug&#xD;
      withdrawal. Thereafter, CBC, KFT, LFT's, PT-INR, HBsAg (Q), HBeAg and HBV DNA levels will be&#xD;
      tested every 3 months. After stopping treatment followup will be done at 24 weeks post&#xD;
      stoppage of treatment to look for sustained seroconversion and virological/biochemical&#xD;
      response&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of funds&#xD;
  </why_stopped>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained [ 6 months after stopping treatment] HBeAg seroconversion to anti-Hbe on two consecutive assays, at least 1 month apart</measure>
    <time_frame>65 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of quantifiable serum HBV DNA</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of serious adverse effects, acute hepatitis or hepatic decompensation</measure>
    <time_frame>64 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HBV</condition>
  <arm_group>
    <arm_group_label>Tenofovir + Interferon alpha 2 b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + Interferon alpha 2b</intervention_name>
    <arm_group_label>Tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil Fumarate</intervention_name>
    <arm_group_label>Tenofovir + Interferon alpha 2 b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Treatment naive chronic HBV infection i.e detectable HBsAg for past 6 months,&#xD;
&#xD;
          2. HBeAg (+),&#xD;
&#xD;
          3. ALT &lt; ULN (Upper Limit Normal) on 2 or more occasions in last 6 months [ULN: 45]&#xD;
&#xD;
          4. HBV DNA &gt;2000 IU/mL&#xD;
&#xD;
          5. Age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated Cirrhosis&#xD;
&#xD;
          2. Severe HBV flare with reactivation&#xD;
&#xD;
          3. Presentation as ACLF (Acute on Chronic liver Failure)&#xD;
&#xD;
          4. Baseline ALT &gt; ULN (Upper Limit Normal)&#xD;
&#xD;
          5. Contraindications to PEG-IFN therapy&#xD;
&#xD;
          6. Prior HBV antiviral therapy within 6 months of enrollment&#xD;
&#xD;
          7. Co-infections with HCV/HIV&#xD;
&#xD;
          8. ANA +(autoantibodies suggestive of autoimmune disease) &gt;1:80&#xD;
&#xD;
          9. Patient not willing for enrollment in the study&#xD;
&#xD;
         10. Pregnancy, lactation&#xD;
&#xD;
         11. Patients who leave the study/ discontinue the therapy before completion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

